Immunome to Present at Guggenheim 3rd Annual Healthcare Innovation Conference
Business Wire•02/11/2026•07:30 ET
0
Key Highlights
- ➤Immunome (IMNM) management to present at Guggenheim healthcare conference November 10, 2026
- ➤Varegacestat NDA accepted by the U.S. FDA
- ➤Pipeline includes four clinical-stage or IND-cleared targeted oncology therapies
Immunome to Present at Guggenheim 3rd Annual Healthcare Innovation Conference
Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that its management will present at the Guggenheim 3rd Annual Healthcare Innovation Conference on November 10, 2026, at 9 a.m. EST.
Get started
Create a free account to read the full story.